Neuroimage Forms Collaborative Relationship with GE Healthcare to Provide Neuroimaging Technologies in Support of Drug Clinical Research

Share Article

Neuroimage today announced a collaborative relationship with GE Healthcare’s Medical Diagnostics Imanet™ business that focuses on advanced neuroimaging and biomarker technologies in support of research clinical trials and preclinical studies. This agreement will make it substantially easier for companies and research facilities to access the technology and expertise that will enable them to speed up their drug development programs.

"Time, money, and effort will be saved with clinical trials through the collaboration of our two companies, especially in the case of difficult or complex projects", according to Adolfo Cotter, President Of NeuroImage

NeuroImage today announced a collaborative relationship with GE Healthcare’s Medical Diagnostics Imanet™ business that focuses on advanced neuroimaging and biomarker technologies in support of research clinical trials and preclinical studies. The Imanet™ network of Positron Emission Tomography (PET) imaging sites provides assistance in all aspects of PET imaging-based clinical trials: from proof-of-concept radiochemistry to clinical imaging, with more than 40 PET tracers for research. NeuroImage is a full service Brain Imaging Contract Research Organization (CRO) that can handle complex projects with more than 60 leading scientists in different subspecialties contributing on an as-needed basis, keeping project overhead down while giving clients the benefit of leading expertise and resources.

Drug development is challenged by the decreasing number of approved innovative drugs for the central nervous system (CNS) and unsustainable research and development costs, despite the emergence of biomarker technologies for pre-clinical and clinical use. Imanet™ and NeuroImage provide integrated technologies across all imaging modalities for pre-clinical and clinical CNS, in conjunction with biomarkers for pharmacokinetics, patient selection and treatment monitoring. These technologies will enable pharmaceutical companies to look at how a drug is delivered to the brain, how a drug interacts with its target, how much drug should be administered for future phase trials, and the biological effects of target engagement. Imaging plays a key role in identifying targets that might enhance diagnosis and treatment. This agreement will make it substantially easier for companies and research facilities to access the technology and expertise that will enable them to speed up their drug development programs.

“We are delighted to be entering this collaboration with Neuroimage,” said Eric Agdeppa, Imaging Solutions Manager. “Our customers are always looking for ways to link pre-clinical and clinical data for efficient translational research and we believe this relationship will give them a service that integrates the tools they need to remove uncertainty in go/no-go decisions in clinical trials.”

According to Adolfo Cotter President and Senior Consultant at NeuroImage: “It is with great pleasure that we put an official stamp on forging a close working relationship with GE Healthcare,” said Adolfo Cotter President and Senior Consultant at NeuroImage. “Our clients will benefit from an end-to-end solution that includes direct access to a network of imaging sites combined with the scientific expertise of our network of medical professionals. Time, money, and effort will be saved with clinical trials through the collaboration of our two companies, especially in the case of difficult or complex projects.”

ABOUT NEUROIMAGE
NeuroImage is a full service Brain Imaging CRO that can handle complex projects at a competitive price. Our international company has more than 60 leading scientists in different subspecialties contributing on an as needed basis, keeping project overhead down while giving clients the benefit of leading expertise and resources. We also are developing Brain Fitness software to enhance normal Creativity and Intelligence, and for therapeutic applications. Long term plans include artificial creative devices. Visit the NeuroImage website at http://www.neuroimageinc.com

ABOUT GE HEALTHCARE
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems. Our “heathymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professional and their patients in more than 100 countries. About Imaging Solutions and Imanet™ An integral part of GE Healthcare’s Medical Diagnostics business, Imanet™ is a network of clinical PET centers conducting exploratory phase PET imaging studies to aid in the development of products for the pharmaceutical industry since 2001. For more information about GE Healthcare, visit http://www.gehealthcare.com/ and http://www.imanet.com.

Contact info: Dr. Adolfo Cotter, +1.416.457.5699
Dr. Eric Agdeppa, +1.609.514.6018

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Adolfo Cotter
Visit website